The Society of Interventional Oncology (SIO) has today announced that Johns Hopkins University in Baltimore, USA, has been approved to commence enrolment and has subsequently enrolled its first patient in the society’s second clinical trial, Tribute, a multicentre observation trial of symptomatic high-risk bone metastases treated with percutaneous ablation and palliative radiation therapy. The Tribute study at Johns Hopkins University will be led by site principal investigators Majid Khan and Kristin Redmond.
The Tribute study clinical leadership includes Jack Jennings and Clifford Robinson at Washington University School of Medicine in St. Louis, USA and Sean Tutton and James Urbanic at the University of California, San Diego, USA. “We are excited to share that Johns Hopkins University is our eighth site activated and has enrolled their first patient in the Tribute trial,” said Jennings. “We look forward to announcing other sites in the USA as they are approved for enrolment.”
The Tribute study is collectively supported by the study’s exclusive pioneer trial partner, Varian, a Siemens Healthineers, the study’s catalyst trial partner, Stryker, and the study’s advocate trial partner, Boston Scientific.
This is the first prospective, multicentre study to evaluate real-world outcomes (e.g., pain, patient-reported outcomes, skeletal-related events, healthcare utilisation) in adult patients treated with both percutaneous ablation and palliative radiation therapy for symptomatic, high-risk metastatic bone lesions. The study was collaboratively designed and developed in partnership with radiation oncology, which SIO sees as a critical multidisciplinary partner to the success of the study. Upon completion, the study will enrol 120 subjects from 10 sites in the USA.
